Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

Stock Research Monitor: ELGX, GKOS, and VLRX

LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on XRAY sign up now at www.wallstequities.com/registration. On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday’s trading session in bearish territories. Taking into consideration yesterday’s market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

DENTSPLY SIRONA

On Monday, shares in York, Pennsylvania headquartered DENTSPLY SIRONA Inc. recorded a trading volume of 1.58 million shares. The stock ended at $47.69, rising 0.87% from the last trading session. The Company’s shares have gained 9.28% in the last month. The stock is trading above its 50-day moving average by 5.75%. Furthermore, shares of DENTSPLY SIRONA, which designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide, have a Relative Strength Index (RSI) of 66.55. Get the full research report on XRAY for free by clicking below at:

www.wallstequities.com/registration/?symbol=XRAY

Endologix

Irvine, California headquartered Endologix Inc.’s stock finished yesterday’s session 0.20% lower at $4.91. A total volume of 269,546 shares was traded. The Company’s shares have gained 13.92% over the previous three months. The stock is trading below its 50-day moving average by 13.41%. Furthermore, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have an RSI of 28.16. To experience our free membership services anytime/ anywhere and access the free report on ELGX, click to register at:

www.wallstequities.com/registration/?symbol=ELGX

Glaukos

At the close of trading on Monday, shares in San Clemente, California headquartered Glaukos Corp. saw a drop of 0.55%, ending the day at $39.55. The stock recorded a trading volume of 231,626 shares. The Company’s shares have advanced 17.43% in the previous three months. The stock is trading above its 200-day moving average by 20.67%. Moreover, shares of Glaukos, which focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma, have an RSI of 43.83. Join our big investor community at Wall St. Equities today and get your free report on GKOS at:

www.wallstequities.com/registration/?symbol=GKOS

Valeritas Holdings

Bridgewater, New Jersey headquartered Valeritas Holdings Inc.’s shares ended the day 3.31% lower at $1.46 with a total trading volume of 151,645 shares. The stock has gained 7.35% in the last month. The Company’s shares are trading below their 50-day moving average by 4.85%. Additionally, shares of Valeritas Holdings, which focuses on the development and commercialization of technologies to treat patients with Type-2 diabetes in the US and China, have an RSI of 47.18.

On July 05th, 2018, research firm Oppenheimer initiated an ‘Outperform’ rating on the Company’s stock, with a target price of $3.50 per share. Know more about VLRX in our free research coverage at:

www.wallstequities.com/registration/?symbol=VLRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 507469